Safety and Efficacy of Biophoton Quantum Medicine in the Treatment of Neurodegenerative Diseases

Abstract

Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis represent a significant and growing public health burden worldwide. Existing pharmacologic therapies primarily offer symptomatic relief and have limited efficacy in halting disease progression or reversing neuronal damage. Biophoton Quantum Medicine (BQM) is an emerging, non-invasive therapeutic approach that utilizes coherent biophoton emissions ultra-weak photon energy naturally produced by biological systems to modulate cellular and neurological function. This review explores the foundational principles of BQM, including its proposed mechanisms of action on mitochondrial bioenergetics, redox balance, neuroinflammation, and neural plasticity. Preclinical data in animal models demonstrate neuroprotective effects, while preliminary clinical observations suggest improvements in cognition, motor function, speech, sleep quality, and overall quality of life in patients with neurodegenerative conditions. BQM has shown a favorable safety profile, with no significant adverse events reported to date. Given its mechanistic plausibility and early clinical promise, BQM warrants further investigation through well-designed randomized controlled trials to establish its therapeutic value and integration into standard neurological care.